Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Eohilia (budesonide oral suspension) is a prescription corticosteroid medication FDA-approved in February 2024 for the treatment of eosinophilic esophagitis (EoE) in patients 11 years of age and older. EoE is a chronic immune-mediated condition where eosinophils (a type of white blood cell) build up in the esophagus, causing inflammation, difficulty swallowing, and food impaction. Eohilia is specifically formulated as a swallowed oral suspension designed to coat the esophagus and reduce this inflammation over a 12-week treatment course.
Eohilia contains budesonide, a synthetic corticosteroid that reduces inflammation in the esophagus by suppressing the immune response and decreasing eosinophil accumulation in esophageal tissue. When swallowed, the suspension coats the lining of the esophagus, delivering the anti-inflammatory medication directly where it's needed. Patients should not eat, drink, or brush their teeth for at least 30 minutes after taking Eohilia to allow the medication to remain in contact with the esophageal tissue.
Eohilia has a findability score of 40 out of 100, making it moderately difficult to locate. As a specialty medication launched in February 2024, Eohilia is distributed through a limited network of specialty pharmacies rather than standard retail pharmacies. This restricted distribution model means you won't find it at your local CVS or Walgreens. Patients typically need to work with their prescriber's office to identify an in-network specialty pharmacy that carries Eohilia.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Eohilia is most commonly prescribed by gastroenterologists, allergists/immunologists, and pediatric gastroenterologists. Since eosinophilic esophagitis typically requires an endoscopy with biopsy for diagnosis, you'll generally need to see a specialist before starting Eohilia. Follow-up prescriptions may be managed via telehealth in some cases.
No, Eohilia is not a controlled substance and has no DEA scheduling. It is a prescription-only medication but does not carry the restrictions associated with controlled substances.
Eohilia is an important treatment option for patients with eosinophilic esophagitis, offering the first FDA-approved budesonide oral suspension specifically designed for this condition. However, its high cash price of nearly $2,000 per month and limited specialty pharmacy distribution can make access challenging. If you're struggling to find Eohilia, contact Takeda's HELP at Hand patient assistance program or use the manufacturer copay card to reduce costs. Medfinder can help you locate specialty pharmacies that have Eohilia in stock near you.
%2C%20Color%3DOriginal.png)
